Phase 4 N=115 Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=211 Sequenced Therapies for Comorbid and Primary Insomnias
Insomnia Comorbid to Psychiatric Disorder · Primary Insomnia
Primary: Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index — 40.00; 34.94; 37.04; 48.15 percent remitted
N/A N=137 Sleep Specialty Consultation: Improving Management of Sleep Disorders
Sleep Disorders
Primary: Provider Adherence to Sleep Specialist Recommendations — 4; 0; 8; 4 participants
N/A N=188 Sleep Without Insomnia or The Use of Chronic Hypnotics
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039
Phase 2 N=67 Study of Sleep-maintenance Activity of 3 Doses of SKP-1041
Sleep Disorder · Primary Insomnia
Primary: Wake After Sleep Onset During Hours 3 to 7 Post-dose (WASO 3-7) — -40.19; -48.79; -50.17; -49.34 minutes — p=0.0118
N/A N=45 A High Density EEG Comparison of Sleep Patterns in Insomnia
Primary Insomnia
Primary: EEG Power During Sleep — 1.40; 1.17 μV^2/Hz — p=0.2791
N/A N=20 Sleep Loss and Mechanisms of Impaired Glucose Metabolism
Primary Insomnia
Primary: Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test — .33; -0.10 %/min, slope of natural log glucose
Phase 3 N=28 The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial
Sleep Disturbance · Craving · Cortisol; Hypersecretion
Primary: Change in Total Sleep Time as Measured by Actigraphy and Sleep Logs Relative to Baseline Over the Course of 7 Days of Treatment With Suvorexant in Substance Use Disorder…
N/A N=1,385 Sleep to Prevent Evolving Affecting Disorders
Insomnia, Primary · Depression
Primary: Severity of Depression as Measured by the Quick Inventory of Depressive Symptomatology (QIDS) Pre-Treatment — 10.8; 10.8 score on a scale
N/A N=489 Implementing and Sustaining a Sleep Treatment to Improve Community Mental Part 1: Implementation Health Outcomes
Sleep Disorder · Circadian Dysregulation
Primary: Patient-level Outcome: Patient-Reported Outcomes Measurement Information System - Sleep Disturbance — 63.86; 62.10; 62.81; 62.80 T-score — p=<0.001
N/A N=92 Sleep IntervEntion as Symptom Treatment for ADHD
ADHD · Sleep · Adolescents
Primary: Sleep Architecture Objective TST [Total Sleep Time] Pre-test to Post-test — 8.11; 7.94; 8.03; 8.07 hours — p=.17
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
N/A N=59 Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence
Alcohol Dependence · Insomnia
Primary: Percentage of Total Sleep Time in Stage 2 Sleep Pre- and Post-study Medication (Stage 2 Percent) — 51.3; 53.8; 50.2; 59.6 percentage of total sleep time
N/A N=121 A Transdiagnostic Sleep and Circadian Treatment to Improve Community SMI Outcomes
Mental Disorders
Primary: Impairment (Sheehan Disability Scale) — 14.30; 12.03; 11.76; 6.57 score on a scale — p=0.025
Phase 4 N=20 Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing
Insomnia · Primary Insomnia · Psychophysiologic Insomnia
Primary: Sleep Latency (SL) — 1; 2; 3; 0 participants
N/A N=54 Adjunctive Brief Behavioral Treatment of Insomnia (BBTI) for Sleep Intervention (SI)
Insomnia · Depression · Posttraumatic Stress Disorder
Primary: Columbia Suicide Severity Rating Scale (C-SSRS) — 5.4; 8.4 units on a scale — p=.153
Phase 2 N=42 Effectiveness of BBT-I and Zopiclone for Chronic Insomnia
Insomnia Chronic
Primary: Insomnia Severity Index — 18.6; 18.9; 13.1; 14.0 units on a scale
Phase 3 N=57 Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
Non-24-Hour Sleep-Wake Disorder
Primary: Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD. — 9; 2 participants
Phase 3 N=119 Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia
Fibromyalgia · Sleep Disorders
Primary: Wake After Sleep Onset (WASO) at Weeks 5 and 11 — 70.69; 51.54 Minutes — p=<0.0001
Phase 3 N=30 Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone
Parkinson's Disease · Insomnia
Primary: TST — 5.7; 6.0 hours
Phase 3 N=127 The Role of Sleep in the Treatment of Cannabis Use Disorders
Drug Addiction
Primary: Sleep Efficiency as Assessed by Percentage of Time Asleep While in Bed — 78; 74 percentage of time asleep while in bed
N/A N=27 Multicomponent Behavioral Sleep Intervention for Insomnia in Older Adults With Mild Cognitive Impairment
Mild Cognitive Impairment · Insomnia
Primary: Sleep Latency — 28.51; 47.06 minutes
N/A N=28 The Psychoneuroimmunology of Insomnia
Primary Insomnia
Primary: Positive Antibody Response — 7; 7 participants
Phase 3 N=125 Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
Sleep Disorders
Primary: Total Sleep Time (TST) — 51.03; 18.71 minutes — p==0.035
Phase 2 N=20 Zaleplon in HIV Patients With Depression
HIV/AIDS · Clinical Depression
Primary: Insomnia Severity Index (ISI) — 11 score on a scale
N/A N=30 Chronic Insomnia and CSF Markers of Dementia
Insomnia Chronic
Primary: CSF Markers Related to Dementia — 4332.1; 4824.0; 393.2; 419.4 picograms per milliliter
Phase 4 N=50 Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder
Seasonal Affective Disorder
Primary: Sleep Satisfaction at Baseline and Measured Monthly, as Measured by the Pittsburgh Sleep Quality Index (PSQI) — 11.56; 11.45; 9.52; 8.67 scores on a scale
N/A N=16 Sleep Length and Circadian Regulation in Humans
Sleep Disorders
Primary: Dim Light Melatonin Onset (Hours) — 1.93; 0.80 hours
Phase 3 N=150 TRIAD - Treatment of Insomnia and Depression
Sleep Initiation and Maintenance Disorders · Depression
Primary: Percent of Participants With Depression Remission — 36.0; 43.8 percentage of participants in arm
Phase 4 N=103 Reducing Suicidal Ideation Through Insomnia Treatment
Insomnia · Depression · Suicidal Ideation
Primary: Scale for Suicide Ideation Index (SSI) — 4.66; 5.25 units on a scale